Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 27, 2009

RXi Gains Rights to Advirna’s RNAi Delivery Platform

  • RXi Pharmaceuticals exercised its option to acquire an exclusive, worldwide license to Advirna’s RNAi delivery technology. The technologies licensed from Advirna encompass four approaches, focused primarily on self-delivery of RNAi therapeutics.

    Advirna’s technology has been integrated into RXi’s rxRNA™ platform to generate so-called self-delivering rxRNAs (sd-rxRNAs), which the company maintains require no separate delivery vehicle such as liposomes, complexes, or nanoparticles. Additional advantages of the new sd-rxRNAs are reported to include their spontaneous cellular uptake, patient-friendly (subcutaneous) administration, tissue-targeted biodistribution/reduced renal clearance, and reduced side-effects. 

    “The ability to create self-delivering RNAi therapeutics promises to provide significant competitive advantages in efficacy, toxicity, ease of administration, and manufacturing costs,” states RXi president and CEO, Tod Woolf, Ph.D.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »